JNJ TECVAYLI Wins EU Approval for Multiple Myeloma Treatment

Johnson & Johnson (JNJ) has received European Commission approval for TECVAYLI (teclistamab) plus daratumumab as a treatment for adult patients with relapsed or refractory multiple myeloma.

The expanded label adds a new therapeutic option within Johnson & Johnson's multiple myeloma portfolio and may influence its European oncology franchise over time.

This decision moves TECVAYLI plus daratumumab into earlier line use for relapsed or refractory multiple myeloma in adults, widening the potential treated population in Europe. It strengthens Johnson & Johnson’s position in multiple myeloma, where the company already has a portfolio of therapies across different treatment stages.

This approval aligns with Johnson & Johnson's narrative that it is focusing on next-generation therapies in oncology and immunology to support its Innovative Medicine segment. It adds another data point alongside assets such as Rybrevant and TECVAYLI and TALVEY combinations, as the company seeks to address loss of exclusivity and policy risks.

Investors can watch how quickly European treatment guidelines and hospital formularies adopt TECVAYLI plus daratumumab and what share it takes relative to existing multiple myeloma regimens. Over time, prescription trends, duration of therapy, and real-world safety data in second-line use will help indicate how significant this indication becomes.